Functional benefits of PLGA particulates carrying VEGF and CoQ10 in an animal of myocardial ischemia

International Journal of Pharmaceutics

Volumn 454, Issue 2, 2013, Pages 784-790

  Simoń Yarza, Teresa ^a   Tamayo, Esther ^a   Benavides, Carolina ^b   Lana, Hugo ^a   Formiga, Fabio R ^a   Grama, Charitra N ^c   Ortiz de Solorzano, Carlos ^b   Ravi Kumar, M N V ^c   Prosper, Felipe ^d   Blanco Prieto, Maria J ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

^c UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^d UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

Angiogenesis; Myocardial ischemia; Protein delivery; Tissue engineering; VEGF

Indexed keywords

NANOPARTICLE; POLYGLACTIN; UBIDECARENONE; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BIOLOGICAL ACTIVITY; CELL ASSAY; CENTRIFUGATION; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; ENCAPSULATION; FEMALE; FREEZE DRYING; HEART EJECTION FRACTION; HEART FAILURE; HEART FUNCTION; HEART MUSCLE ISCHEMIA; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; RAT;

ANGIOGENESIS; CARDIOVASCULAR DISEASE; COENZYME Q(10); COQ(10); CVD; DCM; DDS; DICHLOROMETHANE; DIMETHYLSULFOXIDE; DMSO; DRUG DELIVERY SYSTEM; EF; EJECTION FRACTION; HUMAN UMBILICAL VEIN ENDOTHELIAL CELL; HUVEC; MI; MICROPARTICLE; MP; MYOCARDIAL ISCHEMIA; NANOPARTICLE; NP; PEG; PLGA; POLY (ETHYLENE GLYCOL); POLY (LACTIC-CO-GLYCOLIC) ACID; POLY (VINYL ALCOHOL); PROTEIN DELIVERY; PVA; TISSUE ENGINEERING; TOTAL RECIRCULATION ONE MACHINE SYSTEM; TROMS; VASCULAR ENDOTHELIAL GROWTH FACTOR; VEGF;

ANIMALS; CELL PROLIFERATION; CORONARY VESSELS; DISEASE MODELS, ANIMAL; FEMALE; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; LACTIC ACID; MYOCARDIAL ISCHEMIA; MYOCARDIUM; NANOPARTICLES; NEOVASCULARIZATION, PHYSIOLOGIC; POLYGLYCOLIC ACID; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT PROTEINS; STROKE VOLUME; UBIQUINONE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84884151469     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2013.04.015     Document Type: Article

References (37)

1. 10 for treatment of hypertension: can the simple nutritional supplements be used as first line therapeutic agents for prophylaxis/therapy? Eur. J. Pharm. Biopharm. 67, 361-369.
2. Baker, M.I., Walsh, S.P., Schwartz, Z., Boyan, B.D., 2012. A review of polyvinyl alcohol and its uses in cartilage and orthopedic applications. J. Biomed. Mater. Res. B: Appl. Biomater. 100, 1451-1457.
3. 10: an extensive review of patents. Recent Patents on Drug Delivery and Formulation 4, 245-255.
4. Benavides-Vallve, C., Corbacho, D., Iglesias-Garcia, O., Pelacho, B., Albiasu, E., Castaño, S., Muñoz-Barrutia, A., Prosper, F., Ortiz-de-Solorzano, C., 2012. New strategies for echocardiographic evaluation of left ventricular function in a mouse model of long-term myocardial infarction. PLoS ONE 7, http://dx.doi.org/10.1371/journal.pone.0041691.
5. Burgoyne, J.R., Mongue-Din, H., Eaton, P., Shah, A.M., 2012. Redox signaling in cardiac physiology and pathology. Circ. Res. 111, 1091-1106.
6. Chopra, R.K., 2001. Coenzyme Q products exhibiting high dissolution qualities. U.S. Patent number 6,300,377.
7. Dai, Y.L., Luk, T.H., Yiu, K.H., Wang, M., Yip, P.M., Lee, S.W., Li, S.W., Tam, S., Fong, B., Lau, C.P., Siu, C.W., Tse, H.F., 2011. Reversal of mitochondrial dysfunction by coenzyme Q10 supplement improves endothelial function in patients with ischaemic left ventricular systolic dysfunction: a randomized controlled trial. Atherosclerosis 216, 395-401.
8. DeMerlis, C.C., Schoneker, D.R., 2003. Review of the oral toxicity of polyvinyl alcohol (PVA). Food Chem. Toxicol. 41, 319-326. (Pubitemid 36015770)
9. Eckhouse, S.R., Spinale, F.G., 2012. Changes in the myocardial interstitium and contribution to the progression of heart failure. Heart Failure Clinics 8, 7-20.
10. Formiga, F.R., Pelacho, B., Garbayo, E., Abizanda, G., Gavira, J.J., Simon-Yarza, T., Mazo, M., Tamayo, E., Jauquicoa, C., Ortiz-de-Solorzano, C., Prósper, F., Blanco-Prieto, M.J., 2010. Sustained release of VEGF through PLGA microparticles improves vasculogenesis and tissue remodeling in an acute myocardial ischemia-reperfusion model. J. Control. Release 147, 30-37.
11. Formiga, F.R., Tamayo, E., Simón-Yarza, T., Pelacho, B., Prósper, F., Blanco-Prieto, M.J., 2012. Angiogenic therapy for cardiac repair based on protein delivery systems. Heart Fail. Rev. 17, 449-473.
12. 10 supplementation on heart failure: a meta-analysis. Am. J. Clin. Nutr. 97, 268-275.
13. Garbayo, E., Ansorena, E., Lanciego, J.L., Aymerich, M.S., Blanco-Prieto, M.J., 2008. Sustained release of bioactive glycosylated glial cell-line derived neurotrophic factor from biodegradable polymeric microspheres. Eur. J. Pharm. Biopharm. 69, 844-851.
14. Gullestad, L., Ueland, T., Vinge, L.E., Finsen, A., Yndestad, A., Aukrust, P., 2012. Inflammatory cytokines in heart failure: mediators and markers. Cardiology 122, 23-35.
15. Hervé, M.A., Buteau-Lozano, H., Mourah, S., Calvo, F., Perrot-Applanat, M., 2005. VEGF189 stimulates endothelial cells proliferation and migration in vitro and up-regulates the expression of Flk-1/KDR mRNA. Exp. Cell Res. 309, 24-31. (Pubitemid 41191220)
16. Jaffe, E.A., Nachman, R.L., Becker, C.G., Minick, C.R., 1973. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J. Clin. Invest. 52, 2745-2756.
17. Joshi, D.P., Lan-Chun-Fung, Y.L., Pritchard, J.G., 1979. Determination of poly(vinyl alcohol) via its complex with boric acid and iodine. Anal. Chim. Acta 104, 153-160.
18. Kelly, C.M., DeMerlis, C.C., Schoneker, D.R., Borzelleca, J.F., 2003. Subchronic toxicity study in rats and genotoxicity tests with polyvinyl alcohol. Food Chem. Toxicol. 41, 719-727. (Pubitemid 36349553)
19. Kumar, M.N.V.R., 2012. Can efficient delivery systems leverage benefits of antioxidants leading to potential medicines? Drug Discov. Today 17, 407-408.
20. Lee, B.J., Huang, Y.C., Chen, S.J., Lin, P.T., 2012. Effects of coenzyme Q10 supplementation on inflammatory markers (high-sensitivity C-reactive protein, interleukin-6, and homocysteine) in patients with coronary artery disease. Nutrition 28, 767-772.
21. Littarru, G.P., Tiano, L., Belardinelli, R., Watts, G.F., 2011. Coenzyme Q(10), endothelial function, and cardiovascular disease. Biofactors 37, 366-373.
22. Maksimenko, A.V., Vavaev, A.V., 2013. Antioxidant enzymes as potential targets in cardioprotection and treatment of cardiovascular diseases. Enzyme antioxidants: the next stage of pharmacological counterwork to the oxidative stress. Heart Institute Journal 7, http://dx.doi.org/10.4081/hi.2012.e3.
23. Mitsos, S., Katsanos, K., Koletsis, E., Kagadis, G.C., Anastasiou, N., Diamantopoulos, A., Karnabatidis, D., Dougenis, D., 2012. Therapeutic angiogenesis for myocardial ischemia revisited: basic biological concepts and focus on latest clinical trials. Angiogenesis 15, 1-22.
24. 10: an independent predictor of mortality in chronic heart failure. J. Am. Coll. Cardiol. 52, 1435-1441.
25. 10 are not associated with a lower risk of acute myocardial infarction in Singapore Chinese adults. J. Nutr. 142, 1046-1052.
26. 10 in cardiovascular disease. Mitochondrion 7, S154-S167.
27. Premkumar, V.G., Yuvaraj, S., Vijayasarathy, K., Gangadaran, S.G., Sachdanandam, P., 2007. Serum cytokine levels of interleukin-1beta, -6, -8, tumour necrosis factor-alpha and vascular endothelial growth factor in breast cancer patients treated with tamoxifen and supplemented with co-enzyme Q(10), riboflavin and niacin. Basic Clin. Pharamcol. Toxicol. 100, 387-391. (Pubitemid 46776388)
28. 10, riboflavin and niacin in breast cancer patients undergoing tamoxifen therapy. Vascul. Pharmacol. 48, 191-201.
29. Ratnam, D.V., Chandraiah, G., Sonaje, K., Viswanad, B., Bhardwaj, V., Ramarao, P., Kumar, M.N.V.R., 2008. A potential therapeutic strategy for diabetes and its complications in the form of co-encapsulated antioxidant nanoparticles (NanoCAPs) of ellagic acid and coenzyme Q10: preparation and evaluation in streptozotocin induced diabetic rats. Journal of Biomedical Nanotechnology 4, 33-43.
30. Ratnam, D.V., Chandraiah, G., Meena, A.K., Ramarao, P., Kumar, M.N., 2009. The co-encapsulated antioxidant nanoparticles of ellagic acid and coenzyme Q10 ameliorates hyperlipidemia in high fat diet fed rats. J. Nanosci. Nanotechnol. 9, 6741-6746.
31. 10 and curcumin on inflammatory markers and lipid metabolism in streptozotocin-induced diabetic rats: a possible remedy to diabetic complications. Drug Delivery and Translational Research 1, 448-455.
32. Sherman, W., Martens, T.P., Viles-Gonzalez, J.F., Siminiak, T., 2006. Catheter-based delivery of cells to the heart. Nat. Clin. Pract. Cardiovasc. Med. 3, S57-S64.
33. Simón-Yarza, T., Formiga, F.R., Tamayo, E., Pelacho, B., Prosper, F., Blanco-Prieto, M.J., 2012. Vascular endothelial growth factor-delivery systems for cardiac repair: an overview. Theranostics 2, 541-552.
34. Simón-Yarza, T., Formiga, F.R., Tamayo, E., Pelacho, B., Prosper, F., Blanco-Prieto, M.J., 2013. PEGylated-PLGA microparticles containing VEGF for long term drug delivery. Int. J. Pharm. 440, 13-18.
35. Sohal, R.S., Forster, M.J., 2007. Coenzyme Q, oxidative stress and aging. Mitochondrion 7, S103-S111. (Pubitemid 46712236)
36. Tucka, J., Bennett, M., Littlewood, T., 2012. Cell death and survival signalling in the cardiovascular system. Front. Biosci. 17, 248-261.
37. Wang, B., Cheheltani, R., Rosano, J., Crabbe, D.L., Kiani, M.F., 2013. Targeted delivery of VEGF to treat myocardial infarction. Adv. Exp. Med. Biol. 765, 307-314.